|
1-Aminomethyl-5-methoxyindane (AMMI), is a drug developed by a team led by David E. Nichols at Purdue University, which acts as a selective serotonin releasing agent (SSRA) and binds to the serotonin transporter with similar affinity to DFMDA.〔Roman DL, Saldaña SN, Nichols DE, Carroll FI, Barker EL. Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. ''Journal of Pharmacology and Experimental Therapeutics''. 2004 Feb;308(2):679-87. PMID 14593087〕〔Walline CC, Nichols DE, Carroll FI, Barker EL. Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. ''Journal of Pharmacology and Experimental Therapeutics''. 2008 Jun;325(3):791-800. PMID 18354055〕 == See also == * 2CB-Ind * 5-IAI * Jimscaline * MDAI * MMAI * NM-2-AI * PMA 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「1-Aminomethyl-5-methoxyindane」の詳細全文を読む スポンサード リンク
|